Kanagawa, Japan

Hiroyuki Nagamiya

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Osaka, JP (2012)
  • Kanagawa, JP (2015 - 2017)

Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Hiroyuki Nagamiya: Innovator in Pharmaceutical Compounds

Introduction

Hiroyuki Nagamiya is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target autoimmune diseases and cancer. With a total of 4 patents to his name, Nagamiya's work is recognized for its potential therapeutic applications.

Latest Patents

Nagamiya's latest patents include innovative heterocyclic compounds. One of his notable inventions provides a compound or a salt thereof, which exhibits excellent JAK inhibitory action. This compound is useful as a prophylactic or therapeutic agent for various autoimmune diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, and systemic lupus erythematosus. Another patent focuses on a compound that serves as an agent for the prophylaxis or treatment of autoimmune diseases, showcasing superior Tyk2 inhibitory action.

Career Highlights

Hiroyuki Nagamiya is currently associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda emphasizes the importance of research and innovation in developing effective treatments for complex diseases.

Collaborations

Nagamiya has collaborated with notable colleagues, including Yusuke Ohba and Norihito Tokunaga. These collaborations have contributed to the advancement of research in the pharmaceutical field.

Conclusion

Hiroyuki Nagamiya's contributions to pharmaceutical innovations highlight his commitment to improving health outcomes through scientific research. His patents reflect a dedication to addressing critical medical challenges, particularly in autoimmune diseases and cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…